RxDoctor Payments Data

Andrew Wyant, MD

Family Medicine · Marshall, MONPI 1821087172

Payments from drug & device makers

$1,586in general payments, 2019–2025

Across 104 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$458
  • AstraZeneca$206
  • Amgen$178
  • Novartis$108
  • Merck$100
  • Lilly USA, LLC$81
  • plus $454 from 18 others

What the payments were for

  • Food & beverage$1,55698%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,586 in reported general payments places this provider in the 70th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$62,575
Medicare patients
231
Services billed
668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$69,938
TrulicityDulaglutide30$37,660
JardianceEmpagliflozin43$32,971
MounjaroTirzepatide17$18,091
Spiriva RespimatTiotropium Bromide28$14,670
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$13,945
MyrbetriqMirabegron48$10,945
Combivent RespimatIpratropium/Albuterol Sulfate20$10,440
Bydureon BciseExenatide Microspheres12$10,261
RexultiBrexpiprazole14$9,791
LinzessLinaclotide17$9,342
TrintellixVortioxetine Hydrobromide18$8,623
Spiriva HandihalerTiotropium Bromide18$8,581
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$8,102
Repatha SureclickEvolocumab11$6,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$69,938194 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$13$58,08191 claims
Lilly USA, LLCTrulicity, Mounjaro$81$55,75147 claims
Otsuka America Pharmaceutical, Inc.Rexulti$68$9,79114 claims
AbbVieLinzess$458$9,34217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Marshall

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →